Abstract
Depression and schizophrenia are major psychiatric disorders. Recently it has been documented that these diseases are characterized by deficits and / or loss of neurons in specific brain regions. Nerve growth factor and brainderived neurotrophic factor are endogenous biological mediators involved in neuronal survival and plasticity of dopaminergic, cholinergic, and serotonergic neurons in the central nervous system. Structural, biochemical, and molecular findings led to the hypothesis that these molecules play a role in the pathophysiology of psychiatric disorders and suggested that alterations in expression of neurotrophic factors could be responsible for neural maldevelopment and disturbed neural plasticity both in young, adult and aged subjects. Studies aimed at understanding the mechanisms regulating these events might be an important line of research for analyzing the etiopathogenesis of psychiatric disorders and eventually identifying new methods for diagnosis and new therapeutic strategies.
Keywords: nerve growth factor, brain-derived neurotrophic factor, schizophrenia, depression, serotonergic neurons, neurotrophic factors, neural maldevelopment, neural plasticity, psychiatric disorders
Current Neuropharmacology
Title: Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models
Volume: 1 Issue: 2
Author(s): M. Fiore, F. Angelucci, L. Aloe, A. Iannitelli and J. Korf
Affiliation:
Keywords: nerve growth factor, brain-derived neurotrophic factor, schizophrenia, depression, serotonergic neurons, neurotrophic factors, neural maldevelopment, neural plasticity, psychiatric disorders
Abstract: Depression and schizophrenia are major psychiatric disorders. Recently it has been documented that these diseases are characterized by deficits and / or loss of neurons in specific brain regions. Nerve growth factor and brainderived neurotrophic factor are endogenous biological mediators involved in neuronal survival and plasticity of dopaminergic, cholinergic, and serotonergic neurons in the central nervous system. Structural, biochemical, and molecular findings led to the hypothesis that these molecules play a role in the pathophysiology of psychiatric disorders and suggested that alterations in expression of neurotrophic factors could be responsible for neural maldevelopment and disturbed neural plasticity both in young, adult and aged subjects. Studies aimed at understanding the mechanisms regulating these events might be an important line of research for analyzing the etiopathogenesis of psychiatric disorders and eventually identifying new methods for diagnosis and new therapeutic strategies.
Export Options
About this article
Cite this article as:
Fiore M., Angelucci F., Aloe L., Iannitelli A. and Korf J., Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Schizophrenia and Depression: Findings in Humans, and Animal Models, Current Neuropharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570159033477206
DOI https://dx.doi.org/10.2174/1570159033477206 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Immunopotentiation for Bacterial Biodefense
Current Topics in Medicinal Chemistry Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Beyond the Reproductive Effect of Sex Steroids: Their Role During Immunity to Helminth Parasite Infections
Mini-Reviews in Medicinal Chemistry Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19
Current Neuropharmacology Glycolipids as Immune Modulatory Tools
Mini-Reviews in Medicinal Chemistry Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
Current Protein & Peptide Science B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Overactive Bladder Symptoms in Patients with Fibromyalgia: A Systematic Case-Controlled Study
Reviews on Recent Clinical Trials Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Allergen-Specific Responses of CD19high and CD19low B Cells in Non-IgEMediated Food Allergy of Late Eczematous Reactions in Atopic Dermatitis: Presence of IL-17- and IL-32-Producing Regulatory B Cells (Br17 & Br32)
Inflammation & Allergy - Drug Targets (Discontinued) Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design